DE69830588D1 - Diagnose und behandlung von krankheiten mittels anti-t-zell rezeptor-vbeta-antikörper oder peptide, an denen diese antikörper spezifisch binden, und esrp1 - Google Patents

Diagnose und behandlung von krankheiten mittels anti-t-zell rezeptor-vbeta-antikörper oder peptide, an denen diese antikörper spezifisch binden, und esrp1

Info

Publication number
DE69830588D1
DE69830588D1 DE69830588T DE69830588T DE69830588D1 DE 69830588 D1 DE69830588 D1 DE 69830588D1 DE 69830588 T DE69830588 T DE 69830588T DE 69830588 T DE69830588 T DE 69830588T DE 69830588 D1 DE69830588 D1 DE 69830588D1
Authority
DE
Germany
Prior art keywords
antibodies
esrp1
illnesses
peptides
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69830588T
Other languages
English (en)
Other versions
DE69830588T2 (de
Inventor
Arpi Matossian-Rogers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9715281A external-priority patent/GB2327423B/en
Priority claimed from GBGB9810676.8A external-priority patent/GB9810676D0/en
Application filed by Individual filed Critical Individual
Publication of DE69830588D1 publication Critical patent/DE69830588D1/de
Application granted granted Critical
Publication of DE69830588T2 publication Critical patent/DE69830588T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
DE69830588T 1997-07-21 1998-07-20 Diagnose und behandlung von krankheiten mittels anti-t-zell rezeptor-vbeta-antikörper oder peptide, an denen diese antikörper spezifisch binden, und esrp1 Expired - Lifetime DE69830588T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9715281 1997-07-21
GB9715281A GB2327423B (en) 1997-07-21 1997-07-21 Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis
GB9810676 1998-05-18
GBGB9810676.8A GB9810676D0 (en) 1998-05-18 1998-05-18 Ligands including antibodies showing reactivity against endocrine cells for use in therapy and diagnosis
PCT/GB1998/002151 WO1999005175A2 (en) 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using anti-anti-t-cell receptor vbeta anti-bodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein i (esrp1)

Publications (2)

Publication Number Publication Date
DE69830588D1 true DE69830588D1 (de) 2005-07-21
DE69830588T2 DE69830588T2 (de) 2006-05-04

Family

ID=26311906

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69830588T Expired - Lifetime DE69830588T2 (de) 1997-07-21 1998-07-20 Diagnose und behandlung von krankheiten mittels anti-t-zell rezeptor-vbeta-antikörper oder peptide, an denen diese antikörper spezifisch binden, und esrp1

Country Status (21)

Country Link
US (2) US6689359B1 (de)
EP (2) EP0998556B1 (de)
JP (1) JP2002511765A (de)
KR (2) KR100567277B1 (de)
CN (1) CN1330754C (de)
AT (1) ATE297983T1 (de)
AU (1) AU758455B2 (de)
BR (1) BR9810118A (de)
CA (1) CA2296842C (de)
CU (1) CU23412A3 (de)
DE (1) DE69830588T2 (de)
DK (1) DK0998556T3 (de)
EA (1) EA003131B1 (de)
ES (1) ES2245034T3 (de)
IL (3) IL133277A0 (de)
NZ (1) NZ501424A (de)
PL (1) PL204503B1 (de)
PT (1) PT998556E (de)
SI (1) SI0998556T1 (de)
TR (1) TR200000181T2 (de)
WO (1) WO1999005175A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385879A1 (en) * 1999-09-23 2001-03-29 Rigel Pharmaceuticals, Inc. Traf4 associated cell cycle proteins, compositions and methods of use
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
EP2594591B1 (de) * 2005-08-11 2018-06-06 Arpi Matossian-Rogers Tcr-v-beta-bezogene peptide für die behandlung und diagnose einer autoimmunerkrankung
SG2014013437A (en) 2005-11-30 2014-07-30 Abbott Lab Monoclonal antibodies and uses thereof
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
WO2009048539A2 (en) 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
KR101713365B1 (ko) 2010-07-30 2017-03-08 에이씨 이뮨 에스.에이. 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
US9217172B2 (en) * 2011-09-29 2015-12-22 Cellsnap, Llc Compositions and methods for toxigenicity testing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072356A1 (en) 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
JPH06507384A (ja) * 1991-01-22 1994-08-25 ザ　イミューン　レスポンス　コーポレイション 特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5891623A (en) * 1992-11-09 1999-04-06 Consorzio Per Le Biotecnologie Diagnosis and treatment of AIDS onset
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5589328A (en) * 1994-08-04 1996-12-31 Mahant; Vijay K. Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates

Also Published As

Publication number Publication date
CA2296842A1 (en) 1999-02-04
NZ501424A (en) 2005-08-26
ES2245034T3 (es) 2005-12-16
ATE297983T1 (de) 2005-07-15
TR200000181T2 (tr) 2000-05-22
IL176076A (en) 2010-06-16
JP2002511765A (ja) 2002-04-16
CN1264426A (zh) 2000-08-23
CN1330754C (zh) 2007-08-08
EP1595951A1 (de) 2005-11-16
CA2296842C (en) 2012-03-20
AU758455B2 (en) 2003-03-20
CU23412A3 (es) 2009-09-08
IL133277A (en) 2006-09-05
EP0998556B1 (de) 2005-06-15
KR20010022063A (ko) 2001-03-15
WO1999005175A3 (en) 1999-06-10
AU8451798A (en) 1999-02-16
EA200000146A1 (ru) 2000-10-30
KR100567277B1 (ko) 2006-04-05
US6689359B1 (en) 2004-02-10
US20050100541A1 (en) 2005-05-12
PL204503B1 (pl) 2010-01-29
EA003131B1 (ru) 2003-02-27
PL338449A1 (en) 2000-11-06
SI0998556T1 (en) 2005-10-31
EP0998556A2 (de) 2000-05-10
DK0998556T3 (da) 2005-10-17
KR20050046825A (ko) 2005-05-18
IL133277A0 (en) 2001-04-30
PT998556E (pt) 2005-09-30
BR9810118A (pt) 2000-08-08
DE69830588T2 (de) 2006-05-04
KR100670070B1 (ko) 2007-01-19
IL176076A0 (en) 2006-10-05
WO1999005175A2 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
IL176076A0 (en) Ligands,including antibodies showing, reactivity against endocrine cells
DE69922261D1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
Lukas et al. Inhibition of C1-mediated immune hemolysis by monomeric and dimeric peptides from the second constant domain of human immunoglobulin G.
NO973447D0 (no) Monoklonale antistoffer som er spesifikke for forskjellige epitoper i human-gp 39, og fremgangsmåter for deres anvendelse i diagnose og terapi
DE59705683D1 (de) IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG
CA2266325A1 (en) A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
RU2001126052A (ru) Моноклональные антитела, антигены и их применение для диагностики и терапии злокачественных заболеваний
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
RU2012120706A (ru) Диагностические и терапевтические способы
JP2010519180A5 (de)
JP2005531286A5 (de)
ATE421531T1 (de) Apoptose-bezogene verbindungen und deren verwendung
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
JP2018524575A5 (de)
DE69230881D1 (de) Corticotropinauslösefaktor-bindendes protein
WO2001096372A3 (en) Zinc transporters proteins and their use in medicinal preparations
NO962596L (no) Nytt tumorsupressorgen
Levo et al. Diagnosis and classification of arnyloidosis by an immuno-histological method
DK1254374T3 (da) Fremgangsmåde til diagnose af effektiviteten ved xenotype-antistofbehandling
Ito et al. Immunohistochemical study of utrophin and dystrophin at the motor end-plate in myasthenia gravis
FR2795414B1 (fr) Polypeptide icbp90 et ses fragments et polynucleotides codant lesdits polypeptides et applications au diagnostic et au traitement du cancer
Wallukat et al. Peptides of the AT 1 receptor and their uses
Watkins Characterization of skeletal muscle antibodies in patients with Autoimmune rippling muscles and Myasthenia Gravis, by Thomas C. Watkins.
AU9134198A (en) T-cell antigens, and their use in diagnosis and treatment of T-cell mediated conditions I

Legal Events

Date Code Title Description
8364 No opposition during term of opposition